Zhe Liu

发表

Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression

H. Tao, Hongxia Li, L. Tong, 2020, Bioscience reports.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

[Research progress on the relationship between insulin-like growth factor-I and lung cancer].

W. Yue, Zhe Liu, Qi Li, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

胰岛素生长因子-1受体信号通路与肺癌的研究进展

W. Yue, Zhe Liu, 文涛 Wentao 岳 YUE, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.

W. Wang, Jianxing He, He-long Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[Acceptable safety of bevacizumab therapy in combination with chemotherapy in patients with advanced lung cancer.].

Mingzhi Li, H. Tao, Zan Liu, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma‐induced malignant pleural effusion

Mingzhi Li, H. Tao, Zhe Liu, 2018, Thoracic cancer.

[Long-term survival of a patient with advanced non-small cell lung cancer on bevacizumab therapy: case report and review of the literature].

Mingzhi Li, H. Tao, Zan Liu, 2013, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[Clinical Observation of Erlotinib in the Treatment of Advanced and Previously Treated Non-small Cell Lung Cancer.].

Wei Wu, Mingzhi Li, Zan Liu, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[The relationship between EGFR mutations and response and prognosis of tyrosine kinase inhibitors in advanced Non-small-cell Lung Cancer.].

Wei Wu, Hui Wang, Chunyan Zhang, 2008, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

凡德他尼治疗5例晚期复治肺腺癌患者的临床观察及相关文献回顾

Zhe Liu, Junfang Tang, Lili Guo, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[Adverse events of afatinib as first-line treatment for five cases of advanced lung adenocarcinoma and review of literature].

Wei Wu, Mingzhi Li, H. Tao, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report

Yuqin Qiu, Zhe Liu, Qiang J Li, 2017, OncoTargets and therapy.

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Ying Cheng, Yi-long Wu, B. Han, 2018, Translational lung cancer research.

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively

H. Tao, Zhe Liu, Zhan Huang, 2022, Diagnostic Pathology.

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer

C. Su, Hongxia Li, L. Tong, 2022, Frontiers in Oncology.

[Chinese Expert Consensus on Management of Special Adverse Effects  Associated with Lorlatinib].

Z. Hong, Yong Li, Zhe Liu, 2022, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Lorlatinib for Previously Treated ALK -Positive Advanced NSCLC: Primary Ef ﬁ cacy and Safety From a Phase 2 Study in People ’ s Republic of China

C. Bai, He-long Zhang, Jian-hua Chang, 2022 .

Ef ﬁ cacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Ying Cheng, R. Guo, Yiping Zhang, 2022 .

Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First‐Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung — A Multicenter, Open‐label, Randomized, Phase III Trial

Chengping Hu, Gang Wu, Shun Lu, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.

L. Tong, Zhe Liu, Junfang Tang, 2013, Lung cancer.

Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.

H. Tao, Hongxia Li, Zhe Liu, 2020, Lung cancer.

Expression and clinical significance of mTOR in surgically resected non-small cell lung cancer tissues: a case control study.

Yue Wang, W. Yue, Zhe Liu, 2012, Asian Pacific journal of cancer prevention : APJCP.

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases

Wei Wu, H. Tao, Hongxia Li, 2021, Frontiers in Oncology.

[A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer.].

Wei Wu, Mingzhi Li, H. Tao, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.

Ying Cheng, Y. Shu, Zhijie Wang, 2020, Lung cancer.

Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.

Ying Cheng, C. Bai, He-long Zhang, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase‐positive and surgically resected lung adenocarcinoma

Zhidong Liu, H. Tao, Zhe Liu, 2016, Thoracic cancer.

ALK‐rearranged squamous cell carcinoma of the lung

Shucai Zhang, H. Tao, L. Tong, 2021, Thoracic cancer.

Genetic profiling of circulating cell‐free DNA from cerebrospinal fluid and paired plasma in ALK‐positive lung cancer with brain metastases

Shucai Zhang, H. Tao, L. Tong, 2023, Thoracic cancer.

A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.

Ying Cheng, Jin-Ji Yang, C. Bai, 2020, Lung cancer.

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

Da-ping Yu, L. Tong, Zhe Liu, 2023, Frontiers in Oncology.

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.

X. Chen, Pengxiang Wu, R. Guo, 2023, The Lancet. Respiratory medicine.